Author Archives: admin


Ewing sarcoma: Causes, symptoms, and treatment – Medical News Today

Ewing sarcoma is a form of bone cancer that usually affects children and adolescents.

Ewing sarcoma can be very aggressive, but the cells tend to respond well to radiation therapy. Ideally, doctors will diagnose the cancer before it has spread.

According to the National Library of Medicine, an estimated 250 children in the United States receive a diagnosis of Ewing sarcoma each year.

In this article, learn more about Ewing sarcoma, including the symptoms, causes, and treatment options.

Ewing sarcoma is a rare type of cancer that usually starts in the bone typically in the pelvis, chest wall, or legs and occurs mostly in children and teenagers.

Dr. James Ewing first described Ewing sarcoma in 1921. He identified cancer cells that looked different than the cells in osteosarcoma, another type of bone tumor.

Doctors may also refer to this cancer type as the Ewing family of tumors. These tumors have distinct cells that usually respond well to radiation treatments.

This rare cancer type accounts for just 1.5% of all childhood cancers and is the second most common bone cancer type in childhood, after osteosarcoma.

Although researchers are unsure why some people develop Ewing sarcoma, they have identified mutations in certain genes in the tumor cells that cause this cancer.

These include the EWSR1 gene on chromosome 22 and the FLI1 gene on chromosome 11.

These genetic mutations occur spontaneously during a person's lifetime. The individual does not inherit them from a family member.

There are no known risk factors for Ewing sarcoma that make one person more likely than another to develop this cancer.

Ewing sarcoma can cause the following symptoms:

An estimated 87% of Ewing sarcomas are sarcoma of the bone. The other types form in the soft tissues, such as cartilage, that surround the bones.

Ewing sarcoma can spread to other areas of the body. Doctors call this process metastasis.

Areas that the cancer can spread to include other bones, bone marrow, and the lungs.

Doctors categorize Ewing sarcoma as one of three types according to its extent:

Before diagnosing Ewing sarcoma, a doctor will take a person's full medical history and ask them what symptoms they are having, when they noticed them, and what makes them better or worse. They will also perform a thorough physical exam, focusing on the area of concern.

A doctor will usually recommend an imaging study to view the bone or bones. These tests include:

If it looks as though a tumor may be present, a doctor will perform a biopsy, which involves taking a sample of bone tissue. They will send this tissue to a laboratory, where a specialist called a pathologist will check it for the presence of cancerous cells.

A doctor may also order blood tests, a bone marrow biopsy, and other scans when necessary. These tests can help determine whether the cancer has spread to other locations.

A doctor will work with a team of cancer specialists and surgeons to recommend and implement particular treatments.

Possible treatments for Ewing sarcoma include:

Doctors may use a combination of treatments depending on how far the cancer has spread and a person's overall health.

Research into new treatments for Ewing sarcoma is ongoing. Some doctors may inform their patients about clinical trials, which help test new treatments.

Possible complications of Ewing sarcoma include:

If Ewing sarcoma has spread to other areas of the body, it can be life threatening. For this reason, it is vital for a doctor to evaluate any symptoms as quickly as possible.

According to the American Academy of Orthopaedic Surgeons, an estimated two-thirds of people in whom cancer has not spread to other areas of the body survive at least 5 years after their diagnosis.

People who are more likely to have positive outcomes include those who have:

The likelihood of successful treatment is different for every individual, so people should speak to a doctor about their or their child's expected outlook.

Ewing sarcoma is a rare type of cancer that mostly affects young people.

When doctors detect it early enough, the condition usually responds well to treatment.

Anyone who notices signs or symptoms of Ewing sarcoma, such as a bone that breaks for no apparent reason or a painful lump or swelling, should speak to a doctor.

Follow this link:
Ewing sarcoma: Causes, symptoms, and treatment - Medical News Today

Report: Nurse did not think Clay County inmate needed outside treatment before her death – FirstCoastNews.com WTLV-WJXX

GREEN COVE SPRINGS, Fla. A nurse reportedly told investigators that they didn't believe symptoms were severe enough for outside treatment for a Clay County inmate who died in jail, according to a report by the Florida Department of Law Enforcement.

Michelle Bewley was booked into the Clay County Jail on March 4 on a shoplifting charge. She died in her cell the next day.

The Medical Examiners Office ruled her cause of death was natural due to hypertensive heart disease. The opiate withdrawal was also a contributing factor, according to the medical examiner.

RELATED: Autopsy report reveals cause of death of woman who died in Clay County Jail

The FDLE report states Bewley was experiencing symptoms of drug withdrawal the morning before she died. She told the jail's staff she had not taken heroin in two weeks but was taking medication to get off the drug.

Nurses gave Bewley medications for withdrawal, noting she appeared to be very skinny and highly anxious while being evaluated, according to the report. She also requested a nurse to give her additional medicine. The exact type of medicine Bewley was taking was redacted from the report.

The report says a nurse considered sending Bewley to the hospital but did not think her symptoms were severe enough.

They were like pain screams, Brittany Wink told First Coast News in March. Wink was in a cell near Bewley. Wink said she thought Bewley was dying.

RELATED: 'She was just screaming in pain': Inmate dies at Clay County jail, FDLE now investigating

Medical personnel said Bewley was asleep at around 5 p.m. She was found unresponsive three hours later.

We reached out to the Clay County Sheriffs Office for additional comments from the jail staff and were waiting for a response.

According to the agency, there were no cited deficiencies in the report. The jail was cleared of any wrongdoing but said in a statement that they are changing policies to address inmates medical needs.

We also reached out to the Bewley familys attorney about the case. Were still waiting to hear from them.

See the original post:
Report: Nurse did not think Clay County inmate needed outside treatment before her death - FirstCoastNews.com WTLV-WJXX

No, food companies are not selling products that contain ‘aborted fetus cells’ – PolitiFact

A post shared on Facebook makes a disturbing claim that many popular food and drink companies use "aborted baby fetus cells" to enhance the flavor of their products.

The post features text around a collage of popular food and drink items such as Pepsi, Doritos, Lays, Fritos, Aunt Jemima and Gatorade. It says:

"If only sheeple knew .. that theres a flavor enhancement company called senomyx that puts aborted baby fetus cells in their food and drinks."

The post also has a lengthy caption that appears to be taken entirely from a 2015 blog post by Rich Swier, in which Swier includes this excerpt from a Conservative Post story:

"Kraft, PepsiCo, Nestle, work with Semonyx, a California-based [company] that uses aborted embryonic cells to test fake flavoring chemicals. The aborted human fetal cell line is known as HEK-293, and it is used to see how the human palate will react to synthetic flavors. Since most of todays processed food lacks flavor, companies like Semonyx are hired to develop flavors on their own..."

Swier, according to the blog, holds a doctorate of education from the University of Southern California.

The post was flagged as part of Facebooks efforts to combat false news and misinformation on its News Feed. (Read more about our partnership with Facebook.)

Lets just start off by saying that no neither Kraft nor Pepsi nor any other U.S. food company is selling items to the public that contain "aborted baby fetus cells."

The Conservative Post story that Swiers blog and the Facebook post reference no longer exists on the website, but we traced the controversial claim back to a 2011 dispute involving Senomyx, a San Diego-based biotechnology company, and a pro-life group called Children of God for Life.

According to an archived version of a March 29, 2011, press release from Children of God for Life, the group called for a boycott of food companies that contract with Senomyx. The organization pointed to an April 2002 report by Senomyx researchers as proof that the company was adding HEK 293 Human Embryonic Kidney 293 cells in its research and development to enhance flavor.

HEK 293 is a line of cells originally derived from human embryo kidney cells and that were grown in a tissue culture. The first source of the cells was a fetus that was legally aborted in the Netherlands in the 1970s. The cell line has been widely used in biological and medical inquiry, especially for cancer research.

Fetal stem cell research has been used in cell biology for over 30 years. But no company is manufacturing food or other products intended for human consumption that contain aborted human fetuses.

Senomyx has used the HEK 293 cell line in its flavor research to function as the mouths taste receptor cells, allowing the company to test hundreds of substances. But these cells are not in any of the actual food products that consumers would find on the market. CBS News wrote about this in 2011:

"To non-scientists this may sound a bit strange, but the reality is that HEK 293 cells are widely used in pharmaceutical research, helping scientists create vaccines as well as drugs like those for rheumatoid arthritis. The difference here is that Senomyx's work for Pepsi is one of the first times the cells have (potentially) been used to create a food or beverage. (And it's important to note that no part of a human kidney cell are ever a part of Senomyx's taste enhancers or any finished food products.)"

Gwen Rosenberg, vice president of investor relations and corporate communications for Senomyx, described the process to the Miami New Times during the 2011 controversy and said the process is "basically a robotic tasting system":

"(Rosenberg) depicted rows of little plastic square dishes with hundreds of tiny indentations in each dish. A protein is placed in each indentation, then a flavor. If the protein reacts to the flavor, the results are charted. If the new flavor (of which the company has more than 800,000) is successful with the protein test, the company then conducts taste tests with (live) adult humans."

Science and medicine writer Matthew Herper also broke down the process in a 2012 Forbes article:

"This is 35-year-old technology. And it is widely used in cell biology. And there is no way you'll consume them or that the cells would cause any health problems.

"... The kidney cells were forced to take up bits of DNA using a technique invented in 1973 that used a calcium solution. The resulting cells don't act much like human cells at all, but they are very easy to work with and have become workhorses of cellular biology. That's why they're used in the development of drugs and vaccines. (Here's the original paper on the creation of the HEK cells.) No new fetal tissue has been used to keep the cell culture going; the use of this cell line isn't leading to new abortion."

Our ruling

A Facebook post claims several popular food companies add "aborted baby fetus cells in their food and drinks" for flavor enhancement.

The post mischaracterizes the use fetal stem cell research by biotechnology companies such as Senomyx. HEK 293 cells, a cell line from an aborted fetus from the 1970s, has been widely used in cell biology research for over 30 years in multiple areas, including food and pharmaceutical development. But none of these cells are found in the food products available to consumers.

So, while there is a back-story associated with this post, the claim itself is too inaccurate to rate it anything but False.

See the article here:
No, food companies are not selling products that contain 'aborted fetus cells' - PolitiFact

A Potential New Therapeutic Option for Sickle Cell Disease and b-Thalassemia – P&T Community

WASHINGTON, Oct. 22, 2019 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 244, Issue 14, October 2019) (https://journals.sagepub.com/doi/pdf/10.1177/1535370219872995) reports a possible future treatment option for patients with sickle cell disease and -thalassemia. The study led by Dr. Li Liu in the Department of Biological Sciences at the University of Texas at Dallas in Richardson, Texas (USA), reports that -aminolevulinate (ALA), a heme precursor, can activate fetal -globin expression in erythroid cell systems.

Sickle cell disease (SCD) and -thalassemia are common forms of inherited blood diseases, termed hemoglobinopathies. These disorders negatively impact the quality of life and survival for millions of individuals throughout the world.These diseases are caused by mutations in the adult -globin gene that ultimately result in the production of abnormal hemoglobins. Hemoglobin is the major protein inside red blood cells and delivers oxygen to cells throughout the body.

Prior studies have demonstrated that increased levels of the fetal -globin gene product can lessen the severity in SCD and -thalassemia patients. Hydroxyurea, the first FDA approved therapeutic for SCD, works in part by increasing fetal -globin.Nonetheless, some patients do not respond to treatment with Hydroxyurea. Thus, there is an urgent need to identify new strategies that will increase -globin levels in patients suffering from SCD and -thalassemia.

In the current study, Dr. Liu and colleagues investigated the effects of ALA on -globin expression.Previous studies have shown that exogenous ALA enhances heme synthesis, globin gene expression and hemoglobin production.However, the mechanisms leading to the effects of ALA on -globin expression have not been investigated.This study reports that ALA preferentially activates -globin transcription and translation, thereby inducing fetal hemoglobin synthesis.Mechanistic studies reveal that heme biosynthesis and reactive oxygen species mediate the ability of ALA to induce -globin expression. Dr. Liu said, "These results support future studies to explore the potential of stimulating intracellular heme biosynthesis by ALA or similar compounds as a novel therapeutic strategy for treating SCD and beta-thalassemia."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said, "Researchers in the sickle cell field are currently pursuing many clinical trials that would expand the FDA approved SCD therapeutic choices beyond Hydroxyurea,and the more recently approved Endari. Liu et al have provided in vitro evidence that ALA, through induction of heme biosynthesis, should be considered as a possible future therapeutic option."

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership, visit http://www.sebm.org. Ifinterested in publishing in the journal, please visit http://ebm.sagepub.com.

Related Images

image1.png

View original content to download multimedia:http://www.prnewswire.com/news-releases/a-potential-new-therapeutic-option-for-sickle-cell-disease-and--thalassemia-300942615.html

SOURCE Experimental Biology and Medicine

Link:
A Potential New Therapeutic Option for Sickle Cell Disease and b-Thalassemia - P&T Community

Axovant Presents First Evidence of Clinical Stabilization in Tay-Sachs Disease at the European Society of Gene and Cell Therapy 27th Annual Congress -…

NEW YORK and BASEL, Switzerland, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced preliminary data from an expanded access study administering investigational AXO-AAV-GM2 gene therapy in two patients with infantile Tay-Sachs disease (TSD) at the 27th Annual Congress of the European Society of Gene and Cell Therapy. Infantile TSD, a rapidly progressive and fatal pediatric neurodegenerative genetic disorder, has a median life expectancy of approximately 3-4 years. This data indicates the potential to modify the rate of disease progression in children with infantile TSD.

Todays exciting clinical results from the AXO-AAV-GM2 program are the first reported evidence for potential disease modification in Tay-Sachs disease, and suggest an opportunity for gene replacement therapy to improve outcomes for children with this devastating condition, said Dr. Gavin Corcoran, chief R&D officer at Axovant. Myelination is an important component of healthy brain development in infants and is often abnormal in children with Tay-Sachs disease. We were encouraged to see MRI evidence of preserved brain architecture and improved myelination in the early symptomatic child treated at 10 months of age, coupled with stability of neuromuscular function as measured on the CHOP INTEND scale. We look forward to Dr. Terry Flottes presentation of this data at the ESGCT conference where he will describe these two clinical cases in detail.

Key findings from this first-in-human study in patients treated with AXO-AAV-GM2, an investigational gene therapy designed to restore -Hexosaminidase A enzyme activity in the central nervous system, include:

*CHOP INTEND is a 16-item scale of motor function that has been validated in infants with neuromuscular disorders. Items of motor function are graded from 0 to 4 for each item, where zero equals no response, and 4 equals a complete response. Change from baseline in total score of 4 points or a total score sustained > 40 points has been associated with a clinically meaningful benefit.

Dr. Terence Flotte, Professor of Pediatrics and Dean at the School of Medicine, University of Massachusetts Medical School, said, Bilateral intrathalamic and intrathecal delivery of rAAV gene therapy may surmount the obstacle of providing widespread distribution of therapeutic enzyme throughout the brain and CNS. This innovative delivery could overcome one of the primary challenges for developing treatments for Tay-Sachs, Sandhoff and many other severe pediatric genetic disorders, providing much needed hope for these families.

Dr. Flotte will present this data on AXO-AAV-GM2 in the First-in-Human gene therapy session on October 23, 2019 at 5:30 PM Central European Time (CET).

About AXO-AAV-GM2

AXO-AAV-GM2 is an investigational gene therapy for Tay-Sachs and Sandhoff disease, which rare and fatal pediatric neurodegenerative genetic disorders within the GM2 gangliosidosis family, caused by defects in theHEXA(leading to Tay-Sachs disease) orHEXB(leading to Sandhoff disease) genes that encode the two subunits of the -hexosaminidase A (HexA) enzyme. Both forms of GM2 gangliosidosis are caused by overwhelming storage of GM2 ganglioside within neurons throughout the central nervous system), which is normally degraded in the lysosome by the isozyme HexA. These genetic defects lead to progressive neurodegeneration and shortened life expectancy. AXO-AAV-GM2 aims to restore HexA levels by introducing a functional copy of theHEXAandHEXBgenes via delivery of two co-administered AAVrh8 vectors.

In 2018, Axovant licensed exclusive worldwide rights from the University of Massachusetts Medical School for the development and commercialization of gene therapy programs for GM1 gangliosidosis and GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases.

About Axovant Gene Therapies

Axovant Gene Therapies, part of the Roivant family of companies, is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurological and neuromuscular diseases. Our current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease), and Parkinsons disease.

Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visitwww.axovant.com.

About Roivant

Roivantaims to improve health by rapidly delivering innovative medicines and technologies to patients.Roivantdoes this by buildingVants nimble, entrepreneurial biotech and healthcare companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. Roivant today is comprised of a central technology-enabled platform and 20 Vants with over 45 investigational medicines in clinical and preclinical development and multiple healthcare technologies. For more information, please visitwww.roivant.com.

About the University of Massachusetts Medical School

The mission of the University of Massachusetts Medical School is to advance the health and well-being of the people of the commonwealth and the world through pioneering education, research, public service and health care delivery.

Research into potential therapies for lysosomal storage diseases such as Tay-Sachs, Sandhoff disease and GM1 gangliosidosis at UMass Medical School and Auburn University has led to significant advances in the field. Miguel Sena-Esteves, PhD, associate professor of neurology at UMass Medical School; Heather Gray-Edwards, PhD, DVM, formerly of Auburn and currently assistant professor of radiology at UMass Medical School; and Douglas Martin, PhD, professor of anatomy, physiology and pharmacology in the College of Veterinary Medicine and the Scott-Ritchey Research Center at Auburn University, have worked collaboratively for more than a decade on animal models and therapeutic approaches for these and similar disorders. For more information, visit http://www.umassmed.edu.

Forward Looking Statements and Information

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, might, will, would, should, expect, believe, estimate, and other similar expressions are intended to identify forward-looking statements. For example, all statements Axovant makes regarding the initiation, timing, progress, and reporting of results of its preclinical programs, clinical trials, and research and development programs; cash to be used in operating activities; its ability to advance its gene therapy product candidates into and successfully initiate, enroll, and complete clinical trials; the potential clinical utility of its product candidates; its ability to continue to develop its gene therapy platforms; its ability to develop and manufacture its products and successfully transition manufacturing processes; its ability to perform under existing collaborations with, among others, Oxford Biomedica, and theUniversity of Massachusetts Medical School, and to add new programs to its pipeline; its ability to enter into new partnerships or collaborations; its ability to retain and successfully integrate its leadership and personnel; and the timing or likelihood of its regulatory filings and approvals are forward-looking. All forward-looking statements are based on estimates and assumptions by Axovants management that, although Axovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Axovant expected.Such risks and uncertainties include, among others, the initiation and conduct of preclinical studies and clinical trials; the availability of data from clinical trials; the expectations for regulatory submissions and approvals; the continued development of its small molecule and gene therapy product candidates and platforms; Axovants scientific approach and general development progress; and the availability or commercial potential of Axovants product candidates. These statements are also subject to a number of material risks and uncertainties that are described in Axovants most recent Quarterly Report on Form 10-Q filed with theSecurities and Exchange CommissiononAugust 9, 2019, as updated by its subsequent filings with theSecurities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made.Axovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts:

Media and Investors

Parag MeswaniAxovant Gene Therapies(212) 547-2523investors@axovant.commedia@axovant.com

Read the original here:
Axovant Presents First Evidence of Clinical Stabilization in Tay-Sachs Disease at the European Society of Gene and Cell Therapy 27th Annual Congress -...

Physician-Scientist Christopher Haqq M.D., Ph.D. Joins Elicio Therapeutics as Research and Development Head – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elicio Therapeutics, a next generation immuno-oncology company, announced today that Christopher Haqq M.D., Ph.D. has joined Elicio as Executive Vice President, Head of Research and Development, and Chief Medical Officer.

Chris is an accomplished physician-scientist who brings to Elicio over 20 years of translational drug development and leadership in large and small biotechnology companies across T cell immunotherapy, biologic, and small molecule modalities, commented Elicio CEO Robert Connelly. We expect Chris knowledge of the impact of T-cell expansion, persistence and trafficking in immuno-oncology will dovetail with the unique lymph node targeting ability of Elicios Amphiphile platform.

Before joining Elicio, Dr. Haqq was the first employee and Chief Medical Officer of Atara Biotherapeutics, and later its Chief Scientific Officer, where he was the architect for an innovative pipeline including EBV specific T-cell product candidates for oncology and autoimmune disease, and a next generation off the shelf CAR-T cells for solid tumors. Earlier at Cougar Biotechnology and Janssen, Dr. Haqq was the lead clinician for a pivotal prostate cancer study leading to market approval for Zytiga (abiraterone acetate) and he led early development studies at Amgen.

Dr. Haqq has served as medical monitor for numerous oncology clinical trials working closely with global regulatory agencies. His teams have made successful filings for investigational new drug applications, breakthrough therapy, priority medicines, special protocol assessments and marketing approval and he has authored multiple patents and publications. Dr. Haqq initially practiced as a medical oncologist and led a translational science laboratory as an Assistant Professor in the Division of Hematology/Oncology at the University of California, San Francisco following post-graduate training as an Intern and Resident in Internal Medicine, Fellow in Medical Oncology and Fellow in Molecular Medicine. Dr. Haqq completed his M.D. and Ph.D. in Genetics at Harvard Medical School and his undergraduate training at Stanford University and the University of British Columbia.

I am excited to lead Elicios strong R&D team during the transition from the lab bench to the bedside for its promising lymph node targeted immunotherapies where preclinical monotherapy and CAR-T combination show unique potential, said Dr. Haqq. And as my family has experienced the unmet need for an effective mKRAS therapy, I am looking forward to evaluate ELI-002s safety and efficacy in mKRAS bearing pancreatic, colorectal and lung cancers.

About the Amphiphile Platform

The Elicio Amphiphile platform enables precise targeting and delivery of immunogens and cell-therapy activators directly to the lymphatic system, the brain center of the immune response, to significantly amplify and enhance the bodys own system of defenses, defeat solid and hematologic cancers, and prevent their recurrence. Once in the lymph nodes, Amphiphile immunotherapies are taken up by antigen presenting cells (APCs) to orchestrate signaling to natural or engineered immune cells in order to maximize therapeutic immune responses to disease. This strategy has been used to improve the activity of immunostimulatory agents, antigens, adjuvants, and cell-therapies that generate little to no response when used in the conventional forms. By precisely targeting these immunotherapies to the lymph nodes, Amphiphiles can unlock their full potential to generate and amplify anti-tumor immune responses. This substantially enhanced anti-tumor functionality and long-term protective memory may someday unlock the full potential of the immune response to eliminate cancer.

About Elicio Therapeutics

Elicio Therapeutics is committed to transforming the lives of patients and their families by re-engineering the bodys immune response to defeat cancer. By combining expertise in materials science and immunology, Elicio is engineering potent Amphiphile immunotherapies including lymph node targeted cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers. Elicios lead Amphiphile vaccine targeting KRAS-driven cancers will begin initial patient studies in pancreatic in the first half of 2020. These programs are followed by a broad preclinical pipeline of lymph node targeted immunotherapies. For more information please visit http://www.elicio.com.

Read the original:
Physician-Scientist Christopher Haqq M.D., Ph.D. Joins Elicio Therapeutics as Research and Development Head - Business Wire

Surgeon weighs in on textured breast implants – Washington University School of Medicine in St. Louis

Visit the News Hub

The implants are linked to anaplastic large-cell lymphoma, a rare cancer

Textured breast implants have been linked to a rare and sometimes fatal cancer known as anaplastic large-cell lymphoma. Shown are smooth and textured implants.

The Food and Drug Administration (FDA) announced Oct. 23 a recommendation that manufacturers of breast implants include a boxed warning on implant packaging about the risks associated with the devices, including complications that may require additional surgeries and the development of a rare, sometimes fatal cancer. This past summer Allergan, a global pharmaceutical company, voluntarily recalled its textured breast implants because of links to the cancer, called breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL).

The cancer, a form of non-Hodgkin lymphoma, can reside in the scar tissue and fluid near the breast implant and spread throughout the body, compromising the immune system.

The American Society of Plastic Surgeons has reported 779 cases of BIA-ALCL and at least 33 deaths worldwide since the implants were introduced during the mid-1980s. However, the numbers may be higher because the most recent figures were documented Sept. 3. The majority of implants associated with the incidents were manufactured by Allergan. The cancer has occurred in women who received the implants for cosmetic breast enlargement and for reconstruction after mastectomy for breast cancer.

Similar health concerns have prompted recalls of textured breast implants in other countries.

In a commentary about textured breast implants, published Oct. 23 in JAMA Surgery, Terence M. Myckatyn, MD, a professor of surgery in the Division of Plastic and Reconstructive Surgery at Washington University School of Medicine in St. Louis, recommends smooth-surfaced breast implants for cosmetic and reconstructive patients in his practice.

In most cases, I believe that I can achieve equivalent results with either smooth or textured surface breast implants and that differential outcomes resulting from choosing one device over the other are imperceptible, Myckatyn, a co-author, wrote in the piece. I dont see the value in subjecting my patients to the risk of BIA-ALCL, even if it is only 1 in 3,000. Equally important, I dont see the value in subjecting them to increased anxiety related to their decision. That said, I recognize that there are specific situations where a textured breast implant may have value.

Myckatyn conducts research on textured breast implants and is the senior author of a study published recently in Natures Scientific Reports on breast implants associated with the rare lymphoma.

He shared his expertise:

What advice do you have for women with textured breast implants?

Women who have textured implants do not need them removed. However, they should be monitored at least once a year, and those with implants should immediately contact their physicians if they experience symptoms such as excessive fluid retention around the breast implant, pain, swelling, asymmetry, lumps in the breast or armpit, skin rash or hardening of the breast. Symptoms typically develop seven to nine years after the implant insertion.

It is important to note that women with these implants should not panic. This type of cancer is highly treatable, primarily by removing the implants and scar tissues. It also is very rare. There are several statistics from databases in different countries, but the lifetime risk has been estimated to be 1 in 30,000 women, to 1 in 1,000 women, to the most often cited 1 in 3,000 women. To put it in perspective, the lifetime risk of women developing breast cancer is 1 in 8.

Can you explain the differences between textured and smooth breast implants?

The shells of breast implants can have a textured or smooth surface. The filler can be either silicone or saline. But this is not a silicone versus saline issue. This type of cancer is associated with the breast implant shell. The shells can be round or shaped like a teardrop. Round implants are typically smooth. But all shaped implants have textured shells that act like Velcro to prevent the implant from slipping. The tissues grow into the pores of an implant and secure it from rotating on its axis. This is one of the main reasons for using textured implants. However, most plastic surgeons in the U.S., including myself, use the round, smooth-shell implants. Textured breast implants account for less than 10% of sales here compared with more than 80% of sales abroad. I almost exclusively use round breast implants because I can achieve desirable results with a smooth surface implant. Although the risk for breast-implant-associated lymphoma is rare, I see no reason to subject my patients to potential health risks or to increased anxiety. That said, in certain instances, a textured implant may have value. For example, patients who have issues with one of the breast implants becoming misshapen but not the other breast.

Talk about your recent study looking at texturized breast implants?

The cause of breast-implanted-associated lymphoma is unknown. In the U.S. and all over the world, there havent been many studies, and some of the research we reviewed had holes in the scientific methodology. However, the thought has been that the textured surfaces of the breast implants invite potentially harmful bacteria to thrive in the shells nooks and crannies. The one bacterium that has been implicated is called Ralstonia picketii.

With this as our backdrop, Washington University researchers and collaborators from the University of Texas Health Sciences Center in Houston decided to look at the microbiome. We found Ralstonia in tiny trace amounts, and it was just as likely to be found on the breasts of patients with the cancer as those without. Ralstonia was not in the top 100 organisms that we found. The breast is a gland, so we expected to find a lot of bacteria but we did not find a particular bacterium, or a class of bacteria, that could be associated with the lymphoma. I understand why that was a leading hypothesis. Some other cancers, such as gastric, are associated with a bacterium, and the cancer is treated by killing the bacteria. But that was not the case here.

Our findings are important because they show that unlike gastric cancers that can be prevented by eradicating certain bacteria with antibiotics, this rare lymphoma associated with textured breast implants cannot be prevented with antibiotics, but rather by avoiding textured surface breast implants.

Will you continue to study this problem?

We definitely plan to continue our research on this cancer. Some might think theres no need to bother because its a highly treatable, rare cancer, and these implants have been recalled from future implantation. But already theres been quite a bit of regulatory action, with the FDA and overseas in countries such as France and Denmark. Additionally, its important that we know the facts about the risk so we dont panic unnecessarily. One unfortunate result is that unsavory plastic surgeons may prey upon women with textured implants, urging them to undergo a surgical removal. As I mentioned, this is not recommended for asymptomatic women. However, surgery exposes the women to unnecessary health risks, such as infections, as well as the costs associated with the procedure.

What will you look at next?

Were looking at genetics. Specifically, were researching potential variations in the human genome that may cause the development of breast-implant-associated lymphoma.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Follow this link:
Surgeon weighs in on textured breast implants - Washington University School of Medicine in St. Louis

What Is Going to Happen to Us? Inside ISIS Prison, Children Ask Their Fate – The New York Times

NORTHEASTERN SYRIA The prisoners cover the floor like a carpet of human despair. Many are missing eyes or limbs, some are bone-thin from sickness, and most wear orange jumpsuits similar to what the Islamic State, the terrorist group they once belonged to, dressed its own captives in before it killed them.

Upstairs, jammed into two cells with little sunlight, are more than 150 children ages roughly 9 to 14 from a range of countries. Their parents brought them to Syria and ended up dead or detained. The children have been here for months and have no idea where their relatives are or what the future holds.

I have a question, said a boy from Suriname inside his cell. What is going to happen to us? Are the kids going to come out?

Rare visits to two prisons for former residents of Islamic State-held territory in northeastern Syria by The New York Times this week laid bare the enormity of a growing legal and humanitarian crisis that the world has largely chosen to ignore.

As the Islamic State's self-declared caliphate collapsed in Syria, tens of thousands of men, women and children who had lived in it ended up in squalid camps and crowded prisons run by the Kurdish-led militia that had partnered with the United States to defeat the jihadists.

But now that a military incursion by Turkey against Kurdish forces has set off a new wave of violence and weakened their control over the area, uncertainty has grown over the fate of the huge population of people who survived the toppling of the Islamic State and have been warehoused since then in prisons and detention camps.

Most of their home countries have refused to take them back, fearing that they harbor extremist thoughts or could carry out attacks. So their governments have instead chosen to leave them in the custody of a Kurdish-led force that lacks the resources to house, feed and protect them, much less to investigate the adults and provide the children with education and rehabilitation.

Little about the minors conditions in the Kurdish-run prison appeared to meet international standards that, even for suspected criminals, prioritize children's well-being, consider detention a last resort and require specialized physical and emotional care.

One crowded cell held 86 minors from Syria, Iraq, Mauritius, Russia and elsewhere. Another held 67 adolescents and a boy who said he was 9 and from Russia.

When asked where his parents were, he shrugged and said, They got killed.

Later, he asked of his captors, Why dont they bring us fruit?

The confusion surrounding the detainees has only grown since President Trump started pulling United States forces out of the area, a decision that cleared the way for Turkey to begin its assault on Americas pivotal allies in the war against the Islamic State in Syria.

Prison crowding has increased because Kurdish fighters, who are viewed as a threat by Turkey, moved hundreds of prisoners away from the border to facilities farther from the battle zone, Kurdish officials said. And fighters who worked as prison guards have slipped off to the front lines to fight the Turks, leaving the facilities more vulnerable to prisoner uprisings or attacks by the Islamic State to free its comrades.

We are 100 percent sure that if they have the opportunity to escape from the prison, it will be very dangerous for us, said Can Polat, an assistant warden at a prison with more than 5,000 men. Holding these people here is not only a danger for Syria, it is a danger for the whole world.

The detention crisis in northeastern Syria is a bleak byproduct of the war against the Islamic State.

As the terrorist group was rolled back, losing its last patch of territory in Syria in March, Kurdish fighters found themselves in charge of about 11,000 men and tens of thousands of women and children. Many of them were foreigners, from Europe, Asia, Africa and the Arab world, and most of their countries refused to take them home, even to put them on trial, much less integrate them into society.

So with help from a United States-led international coalition, the Kurds established camps and a prison system, housing detainees in former government prisons they had taken over and in makeshift lock-ups in schools and other facilities.

Mr. Polats prison is a converted industrial institute that now holds more than 5,000 people. One-quarter of them are Syrians, the rest hailing from 29 other countries, including Iraq, Libya, Egypt, Afghanistan, the Netherlands and the United States.

The facility opened around the collapse of the Islamic State in Syria, which caused such an influx of prisoners that many were given orange jumpsuits provided by the coalition to replace their old clothes, Mr. Polat said.

Since the Islamic State often dressed its captives in orange before killing them, many of the captives gasped when they saw the new outfits, thinking they were about to be killed, too.

Orange jumpsuits now filled the prison. Most of the 400 men in a vast medical ward wore them. Many of them were sick or wounded. Men with metal braces holding broken bones in place lay on thin mattresses, while others shuffled to the bathroom on crutches or dragged their legs on the ground behind them.

A few were so emaciated that their cheekbones stuck out and their legs were as thin as arms. When one man made the call to prayer, many of the prisoners prayed sitting down because they were too injured or ill to stand.

The Kurdish guards assumed that most of the men had been fighters and still followed the Islamic States ideology, but the prisoners themselves played down their roles in the worlds most fearsome terrorist organization.

A Palestinian man with a broken leg said he had come to Syria because he wanted to help. A mechanic from Trinidad said he had not fought because he had been too busy fixing cars. A tall, muscular Russian said he had been a cook in an elementary school.

In dozens of interviews in two prisons, no one admitted to being a fighter.

Most wanted to return to their countries or hoped to get amnesty for renouncing the Islamic State.

There are some who say, I was a fighter and will continue on that path, and others who say, No, I was tricked, said Basil Karazoun, who said he had joined the terrorist group for protection after defecting from the Syrian military.

Like most of the prisoners, he feared being handed over to Syrias president, Bashar al-Assad, whose forces have been accused of widespread abuse and killings of detainees. After Mr. Trump announced that he was pulling troops out of Syria, the Kurds worried about being overrun by Turkey once the Americans abandoned them announced that they had reached an agreement to allow Syrian government forces into the area.

Its a fact that if we fall into the regimes hands, there will be mass executions, he said. That is how the regime thinks.

Another cell in the prison held 99 men, most of whom had lost limbs, including Abdelhamid al-Madioum, who described himself as an American who had lived near Minneapolis.

In an interview, he said he had worked at a Jamba Juice in high school, that his best friends were an atheist and a Christian, and that he had been studying engineering before joining the Islamic State in Syria, where he had hoped to study medicine.

But a few months after he arrived, he said, he was hit by an airstrike that shattered his body and tore off his right arm. Around the time he was captured by Kurdish fighters this year, he said, his wife was shot dead and he lost track of his two young sons, aged 2 and 4.

I made a mistake, he said. Ill admit it. Ill admit it 1,000 times.

It was unclear why some minors were put in prison, while most of the children of Islamic State fighters and followers have been taken to detention camps. Their cells were crowded, with no free space between their mattresses and blankets. When a guard swung open a hatch on the cells door, the children crowded around to peek outside.

Mr. Polat, the deputy warden, later said the authorities had indications that many of the minors had been through ideological training as cubs of the caliphate, or future fighters. Plans to move the youngest prisoners to rehabilitation centers had been delayed, he said, because of the Turkish incursion and the lack of international support.

Under United Nations standards for juvenile justice, even minors suspected of crimes should be detained only as a measure of last resort and for the shortest possible period of time, pending trial.

While the Islamic State did train boys for combat, it was unclear if that was true of the boys in the prison. None were awaiting trial, because the Syrian Kurdish authorities do not try foreigners.

The United Nations also says detained juveniles should receive all necessary individual assistance, including education, medical care and counseling.

The boys in prison said they received almost no services.

The situation is pretty bad here, so if they could hurry up and decide, said a 16-year-old boy from Mauritius. Months like this without knowing what is going to happen, people could start going crazy. They could say these guys were terrorists before with ISIS, but they are still human.

The rest is here:
What Is Going to Happen to Us? Inside ISIS Prison, Children Ask Their Fate - The New York Times

Scientists extend mice lifespan 12% by tweaking telomeres – Big Think

Scientists successfully extended the average lifespan of mice by breeding them using embryonic stem cells with extra-long telomeres. The findings are significant because the researchers managed to extend lifespan without genetic modification, and they also shed light on the aging process and techniques that might someday slow it.

The study published October 17 in Nature Communications focuses on telomeres, which are stretches of DNA found at the end of chromosomes.

Because telomeres protect the genetic material inside chromosomes, they've been likened to the plastic tips on the ends of shoelaces. But telomeres have also been compared to bomb fuses, or "molecular clocks," because they become shorter each time a cell divides, eventually shrinking so much that the cell dies or stops dividing. This shortening of our telomeres is associated with aging, cancer, and death.

"Telomere shortening is considered one of the hallmarks of aging as short telomeres are sufficient to cause organismal aging and decreased lifespan," the researchers wrote. "Telomere length is determined genetically and both average telomere length and the rate of telomere shortening varies between species. In this regard, humans are born with shorter telomeres than mice, but mice telomeres shorten 100-times faster than humans."

For years, scientists have been exploring how lengthening telomeres might help stave off disease and aging in animals, and, perhaps someday, in humans. But these attempts have all involved genetic modification. In the new study, a team of researchers at the Spanish National Cancer Research Center left induced stem cells to multiply in a petri dish, a process which eventually results in cells that have extra-long telomeres, as researchers first discovered in 2009.

Using these specially cultivated embryonic stem cells, the team generated mice with extra-long telomeres. Compared to a control group, these mice experienced "significant increase of 12.74 percent in median longevity", showed no cognitive defects and were less likely to develop cancer and obesity.

"This finding supports the idea that, when it comes to determining longevity, genes are not the only thing to consider," says molecular biologist Maria Blasco, from the Spanish National Cancer Research Centre (CNIO). "There is margin for extending life without altering the genes."

Shorter telomeres are linked to a shorter lifespan in humans. And although we're unlikely to see any experiments involving that are similar to the recent study, there are some steps you can take to lengthen your telomeres and increase your chances at a longer life. The main step: endurance exercise.

A 2018 study published in the European Heart Journal found that telomerase activity spikes in people who regularly do endurance exercises, defined as 45 minutes of continuous running. Interestingly, this effect was not observed in people who lifted weights or walked for 45 minutes. The results echoed those of a similar 2017 study, which found that people who ran regularly appeared to be biologically younger than those who didn't. But it takes some effort.

"If you want to see a real difference in slowing your biological aging, it appears that a little exercise won't cut it," study author Larry Tucker told Science Daily. "You have to work out regularly at high levels."

Related Articles Around the Web

Read more from the original source:
Scientists extend mice lifespan 12% by tweaking telomeres - Big Think

Scientists Made Mice Live 12% Longer by Hacking Their Telomeres – Futurism

A team of researchers at the Spanish National Cancer Research Center have managed to extend the average lifespan of lab mice by more than 12 percent by cultivating embryonic cells in a special way,according to Science Alert no genetic modification required.

They looked at a natural process thats linked to aging: the strands of nucleotide sequences at the end of each chromosome, called telomeres,that act as a buffer to protect the genetic material inside the chromosomes. These telomeres tend get shorter over time as we age so longevity researchers have long pondered whether increasing their length could help us live longer.

In this case, the Spanish researchers left stem cells in a petri dish to multiply on their own, giving them unusually long telomeres. Mice bred with chromosomes featuring the twice-as-long telomeres showed a significant increase of 12.74 percent in median longevity, according to the researchers paper, which was published last week by the journal Nature Communications.

They also found that the specially-bred mice showed no difference in cognitive function, retained the longer telomeres over time, and were 20 percent less likely to develop age-related tumors.

The experiment isnt quite as revolutionary as it sounds this kind of technique isnt about to make humans live longer any time soon. But it could give scientists insight into the process of aging and perhaps find ways to slow it down in the future.

Read the original:
Scientists Made Mice Live 12% Longer by Hacking Their Telomeres - Futurism